EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials

Benjamin G Wajda iD, Leah E Ferrie, Annalise G Abbott, Golpira Elmi Assadzadeh, Michael J Monument iD, Joseph K Kendal iD

Cancers · 24.01.2025 · 17 (3) · 388

DOI: 10.3390/cancers17030388 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.01.2025. Verfasst von Benjamin G Wajda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic bone disease (MBD) presents significant challenges in patient management, leading to skeletal-related events (SREs), compromised health-related quality of life, and heightened pain experiences. Denosumab (Dmab) and zoledronic acid (ZA) are bone-modifying agents (BMAs) commonly employed to mitigate the sequelae of MBD. Previous meta-analyses have assessed primary outcomes such as overall survival, pathological fractures, radiation to bone, and the time to SREs within studies. However, a single comprehensive analysis comparing their efficacy across multiple primary and secondary outcomes, as well as cost-effectiveness in specific cancer types, has not yet been conducted.

Methods

A literature search identified relevant randomized controlled trials (RCTs), and the primary outcomes included overall survival, pathologic fractures, radiation to bone, and the time to SREs within studies. Secondary outcomes included adverse events, pain, analgesia usage, quality of life, and cost.

Results

Meta-analysis revealed that Dmab effectively reduced the need for bone-targeted radiation therapy and was superior to ZA in delaying the time to SREs, except in multiple myeloma. Dmab also reduced pathological fracture incidences in breast cancer patients by 39%.

Conclusions

Our analysis suggests that while both agents similarly impact overall survival and disease progression, Dmab offers advantages in SRE reduction and improved HRQoL and pain outcomes with lower rates of opioid usage, albeit with higher risks of hypocalcemia and osteonecrosis in some subgroups. The consensus on cost-effectiveness is mixed and varies based on the cancer type and healthcare system, with some studies favoring Dmab’s superior efficacy and safety, while others find ZA more cost-effective due to its lower cost. This study underscores the potential of Dmab as a preferred BMA for MBD management, especially for high-risk skeletal complications, while highlighting cancer-specific safety considerations. Further research is warranted to refine cancer-specific BMA use and optimize MBD management strategies.

Schlagwörter

Stichwörter der Autor:innen

bone metastasisdenosumabmetastatic bone diseasemultiple myelomazoledronic acid“bone cancer”

Autor:innen und Institutionen

  • Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • McCaig Bone & Joint Institute, University of Calgary, Calgary, AB T2N 1N4, Canada.

ORCID-Profile: Benjamin G Wajda, Michael J Monument, Joseph K Kendal

Zitieren

APA

Wajda, B. G., Ferrie, L. E., Abbott, A. G., Elmi Assadzadeh, G., Monument, M. J., & Kendal, J. K. (2025). Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers, 17(3), 388. https://doi.org/10.3390/cancers17030388

Vancouver

Wajda BG, Ferrie LE, Abbott AG, Elmi Assadzadeh G, Monument MJ, Kendal JK. Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers. 2025;17(3):388. doi:10.3390/cancers17030388

BibTeX
@article{Wajda2025,
  author = {Wajda, Benjamin G and Ferrie, Leah E and Abbott, Annalise G and Elmi Assadzadeh, Golpira and Monument, Michael J and Kendal, Joseph K},
  title = {Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {388},
  doi = {10.3390/cancers17030388}
}
Kostenlos starten →